Expand all sections

Igrelimogene litadenorepvec

Extended indication Treatment of solid tumor patients (melanoma and SCCHN) refractory to or progressing after Anti-PD(L)
Therapeutic value No estimate possible yet
Registration phase Clinical trials

Product

Active substance Igrelimogene litadenorepvec
Domain Oncology
Reason of inclusion New medicine (specialité)
Main indication Oncology other
Extended indication Treatment of solid tumor patients (melanoma and SCCHN) refractory to or progressing after Anti-PD(L) In combination with avelumab
Manufacturer TILT

Registration

Type of trajectory Normal trajectory
ATMP Yes
Submission date 2024
Expected Registration 2025
Registration phase Clinical trials
Additional remarks NCT05222932

Therapeutic value

Therapeutic value No estimate possible yet

Expected patient volume per year

References (1) IKNL 2022; (2) Simeone E, Ascierto PA. Anti-PD-1 and PD-L1 antibodies in metastatic melanoma. Melanoma Manag. 2017 Dec;4(4):175-178. doi: 10.2217/mmt-2017-0018. Epub 2017 Nov 21. PMID: 30190923; PMCID: PMC6094668.
Additional remarks Melanoom van de huid betreft 8.045 patiënten in 2022 (1) 60 tot 70% van de patiënten met gemetastaseerd melanoom reageert niet op Anti-PD therapie (2). Ongeveer 25% van de patiënten met gemetastaseerd melanoom die een response hadden op anti- PD therapie heeft recurrence (2). Voor Plaveiselcelcarcinoom van de huid betreft 14.873 patiënten in 2022 (1).

Expected cost per patient per year

There is currently nothing known about the expected cost.

Potential total cost per year

There is currently nothing known about the possible total cost.

Off label use

There is currently nothing known about off label use.

Indication extension

There is currently nothing known about indication extensions.

Other information

There is currently no futher information available.